Cetrorelix
- Generic Name
- Cetrorelix
- Brand Names
- Cetrotide
- Drug Type
- Small Molecule
- Chemical Formula
- C70H92ClN17O14
- CAS Number
- 120287-85-6
- Unique Ingredient Identifier
- OON1HFZ4BA
- Background
Cetrorelix is a man-made hormone that blocks the effects of Gonadotropin Releasing Hormone (GnRH). GnRH controls another hormone that is called luteinizing hormone (LH), which is the hormone that starts ovulation during the menstrual cycle. When undergoing hormone treatment sometimes premature ovulation can occur, leading to eggs that are not ready for fertilization to be released. Cetrorelix does not allow the premature release of these eggs to occur.
- Indication
For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation
- Associated Therapies
- Controlled Ovarian Stimulation
PPOS Protocol Versus GnRH Anatagonist for Expected Normal Responder Patients Undergoing ART : a Randomized Clinical Trial
- Conditions
- PPOSGnRH AntagonistAssisted Reproductive Techniques
- Interventions
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Kasr El Aini Hospital
- Target Recruit Count
- 328
- Registration Number
- NCT06868576
- Locations
- 🇪🇬
Ciro University Kasr Alainy OBGYN Hospital, Cairo, Alquahira, Egypt
Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!
- Conditions
- PCOS (Polycystic Ovary Syndrome)
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Ahmed Saad
- Target Recruit Count
- 50
- Registration Number
- NCT06608186
- Locations
- 🇪🇬
Hawaa Fertility center, Banhā, Qalyubiya, Egypt
PPOS vs GnRH Antagonist in Ovarian Stimulation (ProGanOS Study)
- Conditions
- Progestins Primed Ovarian Stimulation
- Interventions
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Mỹ Đức Hospital
- Target Recruit Count
- 626
- Registration Number
- NCT06378268
- Locations
- 🇻🇳
My Duc Hospital, Ho Chi Minh City, Vietnam
Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone（GnRH）Antagonist Protocol in Women Undergoing IVF
- Conditions
- Infertility
- Interventions
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Northwest Women's and Children's Hospital, Xi'an, Shaanxi
- Target Recruit Count
- 1338
- Registration Number
- NCT06023602
- Locations
- 🇨🇳
He Cai, Xi'an, None Selected, China
Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes
- Conditions
- IVF
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 387
- Registration Number
- NCT05972902
- Locations
- 🇪🇬
Beni-suef university Hospital, Banī Suwayf, Beni Suef, Egypt
Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist in With Expected High Ovarian Response Undergoing in Vitro Fertilization
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 200
- Registration Number
- NCT05951400
- Locations
- 🇪🇬
Beni-suef university Hospital, Banī Suwayf, Beni Suef, Egypt
Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in ICSI
- Conditions
- Fertility IssuesOvary Cyst
- Interventions
- Other: progestin primed ovarian stimulation protocol
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Zagazig University
- Target Recruit Count
- 79
- Registration Number
- NCT05751681
- Locations
- 🇪🇬
Zagazig University, Zagazig, Egypt
Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures
- Conditions
- Assisted Reproductive TechnologyControlled Ovarian Hyperstimulation
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Bio Genuine (Shanghai) Biotech Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT05738382
- Locations
- 🇨🇳
Site No3, Wuhan, China
🇨🇳Site No7, Guangzhou, China
🇨🇳Site No9, Haikou, China
Progestin-primed Ovarian Stimulation Protocol Versus GnRH Antagonist Protocol in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Cycles
- Conditions
- PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 200
- Registration Number
- NCT05112692
GnRH Antagonist Pre-treatment in the Early Follicular Phase for Resolution of a Baseline Functional Ovarian Cyst
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT04993924
- Locations
- 🇮🇱
Shamir Medical center, Be'er Ya'aqov, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.